

DAFTAR PUSTAKA

- Abd, A. H., 2012. The role of combination of Meropenem with gentamicin in reducing emergence of antibiotic resistance in some highly resistant staphylococcus species in vitro. *Kufa Journal Of Veterinary Medical Sciences*. 3 (2): 143–150.
- Allen, H. K., Donato, J., Wang, H. H., Cloud-Hansen, K. A., *et al.*, 2010. Call of the wild: antibiotic resistance genes in natural environments. *Nature Review Microbiology*. 8: 251-259.
- Barker, C. I. S., Germovsek, E., Hoare, R. L., Lestner, J. M., *et al.*, 2014. Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology. *Advanced Drug Delivery Reviews*, 73, pp.127–139.
- Bramantono, Purwati, & Hamidah, 2013. The Prevalence of Extended Spectrum Beta-Lactamase (ESBL) in Third Generation Cephalosporin Usage Among Patients in Department of Internal Medicine RSUD Dr. Soetomo Surabaya. *Folia Medica Indonesiana*. 49 (4): 244-251.
- Craig, W., 1997. The pharmacology of meropenem, a new carbapenem antibiotic. *Infectious Diseases Society of America*. 24 (2): S266–S275.
- Dewi, R., 2010. Sepsis pada Anak : Pola Kuman dan Uji Kepekaan. *Majalah Kedokteran Indonesia*. 61 (3): 101-106.
- DiPiro, J. T., Talbert, R. L., Yee G. C., Matzke, G. R., *et al.*, 2005. *Pharmacotherapy: A Pathophysiologic Approach 6th ed.* McGraw-Hill, New York.
- El-Din, E. M. R., El-Sokkary, M. M. A., Bassiouny M. R., & Hassan R., 2015. Epidemiology of Neonatal Sepsis and Implicated Pathogens: A Study from Egypt. *BioMed Research International*. doi:10.1155/2015/509484.
- Goldstein, B., Giroir, B. & Randolph, A., 2005. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. *Pediatric critical care medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies*. 6(1): 2–8.
- Goodman, L. S., Brunton, L. L., Chabner, B., & Knollman, B. C., 2006. *Goodman & Gilman's the pharmacological basis of therapeutics 11th ed.* McGraw-Hill, New York.

- Gray, J., Arvelo, W., McCracken J., Lopez B., *et al.*, 2012. American Journal of Infection Control An outbreak of Klebsiella pneumoniae late-onset sepsis in a neonatal intensive care unit in Guatemala. *American Journal of Infection Control*. 40(6): 516–520.
- Hartman, M. E., Linde-Zwirble W. T., Angus D. C., & Watson R. S., 2013. Trends in the epidemiology of pediatric severe sepsis*. *Pediatric Critical Care Medicine*. 14(7):686-93.
- Katzung, B. G., Masters, S. B., & Trevor, A. J., 2009. *Basic and Clinical Pharmacology 11th ed.* McGraw-Hill, New York.
- Khaleq, M. A. A., Abd, A. H., & Dhahi, M. A., 2011. Efficacy of Combination of Meropenem with Gentamicin, and Amikacin against Resistant E. coli Isolated from Patients with UTIs : in vitro Study. *Iraqi Journal of Pharmaceutical Science*. 20(2): 66–72.
- Kumar, D. & Kumari, K., 2013. Klebsilla : In Drinking Water. *International Journal of Pharmaceutical Science Invention*. 2(12): 38–42.
- Ma, L., Lin C., Chen J., Fung C., *et al.*, 2009. Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum β -lactamases. *Antimicrobial Agents and Chemotherapy*. 53(1): 104–111.
- Mansury, D., Motamedifar M., Sarvari J., Shirazi B., *et al.*, 2016. Antibiotic susceptibility pattern and identification of extended spectrum β -lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae from Shiraz, Iran. *Iranian Journal of Microbiology*. 8(1): 55–61.
- Morril, H. J., Pogue, J. M., Kaye, K. S., & LaPlante K. L., 2014. Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. *Open Forum Infectious Disease* 2 (2): 1-15.
- Mutlu, M., Aslan, Y., Saygin, B., Yilmaz G., *et al.*, 2011. Neonatal sepsis caused by gram-negative bacteria in a neonatal intensive care unit: A six years analysis. *Hong Kong Journal of Paediatrics*. 16(4): 253–257.
- Nicolau, D. P., 2008. Pharmacokinetic and pharmacodynamic properties of meropenem. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 47 Suppl 1(Suppl 1), pp.S32-40.
- Orhan, G., Bayram, A., Zer, Y., & Balci, I., 2005. Synergy tests by E test and checkerboard methods of antimicrobial combinations against Brucella melitensis. *Journal of Clinical Microbiology*. 43(1): 140–143.

- Pankey, G. A., Ashcraft, D. S., & Dornelles, A., 2013. Comparison of 3 Etest methods and time-kill assay for determination of antimicrobial synergy against carbapenemase-producing *Klebsiella* species. *Diagnostic Microbiology and Infectious Disease*. 77(3): 220–226.
- Podschun, R. & Ullmann, U., 1998. *Klebsiella* spp. as nosocomial pathogens: Epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clinical Microbiology Reviews*. 11(4): 589–603.
- Pournaras, S., Kristo, I., Vrioni, G., Ikonomidis, A., *et al.*, 2010. Characteristics of meropenem heteroresistance in *Klebsiella pneumoniae* carbapenemase (KPC)-producing clinical isolates of *K. pneumoniae*. *Journal of Clinical Microbiology*. 48(7): 2601–2604.
- Prithadewi, A. A., Hasmono, D., Sukrama, D. M., & Artana, W. D., 2015. Bacterial and antibiotics sensitivity pattern in neonatal sepsis patients. *Folia Medica Indonesiana*. 51 (1): 1-6.
- Rizki, L. P., 2015. Studi Efek Kombinasi Meropenem, Gentamisin, Dan Leuvofloxacin Terhadap Isolat Klinis Multidrug Resistance *Pseudomonas Aeruginosa* (MDR-PA) Dengan Metode E-test. FK UGM.
- Rodríguez-Avial, I., Pena, I., Picazo, J. J., Rodríguez-Avial, C., *et al.*, 2015. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains. *International Journal of Antimicrobial Agents*. 46(6): 616–621.
- Ruppé, É., Woerther, P. L. & Barbier, F., 2015. Mechanisms of antimicrobial resistance in Gram-negative bacilli. *Annals of Intensive Care*. 5(1): 21.
- Shah, B. A. & Padbury, J. F., 2014. Neonatal sepsis: an old problem with new insights. *Virulence*. 5(1): 170–8.
- Simonsen, K. A., Anderson-Berry, A. L., Delair, S. F., & Davies, D., *et al.*, 2014. Early-onset neonatal sepsis. *Clinical Microbiology Reviews*, 27(1), pp.21–47.
- Sivanandan, S., Soraisham, A. S. & Swarnam, K., 2011. Choice and duration of antimicrobial therapy for neonatal sepsis and meningitis. *International journal of pediatrics*. doi:10.1155/2011/712150.
- Sueke, H., Kaye, S. B., Neal, T., Hall, A., *et al.*, 2010. An in vitro investigation of synergy or antagonism between antimicrobial combinations against isolates from bacterial keratitis. *Investigative Ophthalmology and Visual Science*. 51(8): 4151–4155.

- Tamma, P. D., Cosgrove, S. E., & Maragakis, L. L., 2012. Combination Therapy for Treatment of Infections with Gram-Negative Bacteria. *Clinical Microbiology Reviews*. 25(3): 450–470.
- Tanwar, J., Das, S., Fatima, Z., & Hameed S., 2014. MDR: An emerging crisis. *Interdisciplinary Perspectives on Infectious Diseases*. doi: 10.1155/2014/541340.
- Van belkum, A., Halimi, D., Boneeti, E., Renzi, G., *et al.*, 2015. Meropenem/colistin synergy testing for multidrug-resistant *Acinetobacter baumannii* strains by a two-dimensional gradient technique applicable in routine microbiology. *Journal of Antimicrobial Chemotherapy*. 70(1): 167–172.
- Vazquez-Grande, G. & Kumar, A., 2015. Optimizing Antimicrobial Therapy in Sepsis and Septic Shock. *Critical Care Nursing Clinics of North America*. 1(212): 154–166.
- Ventola, C. L., 2015. The antibiotic resistance crisis: part 1: causes and threats. *P & T: A peer-reviewed journal for formulary management*. 40(4): 277–83.
- Weiss, S. L., Fitzgerald, J. C., Pappachan, J., Wheeler, D., *et al.*, 2015. Global Epidemiology of Pediatric Severe Sepsis: The Sepsis Prevalence, Outcomes, and Therapies Study. *American Journal of Respiratory and Critical Care Medicine*. 191(10): 1147–1157.
- White, R. L., Burgess, D. S., Manduru, M., & Bosso, J. A., 1996. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. These include: Comparison of Three Different In Vitro Methods of Detecting Synergy: Time-Kill, Checkerboard, and E test. *Antimicrobial Agent And Chemotherapy*. 40(8): 1914–1918.
- Xu, Y., Gu, B., Huang, M., Liu, H., *et al.*, 2015. Epidemiology of carbapenem resistant Enterobacteriaceae (CRE) during 2000-2012 in Asia. *Journal of Thoracic Disease*. 7(3): 376–385.
- Zarkotou, O., Pournaras, S., Tselioti, P., Dragoumanos, V., *et al.*, 2011. Predictors of mortality in patients with bloodstream infections caused by KPC-producing *Klebsiella pneumoniae* and impact of appropriate antimicrobial treatment. *Clinical Microbiology and Infection*. 17(12): 1798–1803.
- Zhanell, G.G., Simor, A.E., Vercaigne, L., & Mandell, L., 1998. Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. *The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses*. 9(4): 215–228.